In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health Discovery Corp.

www.healthdiscoverycorp.com

Latest From Health Discovery Corp.

Diagnostics In 2015: Past Trends Coalesce, New Roads Open

The introduction of Apple’s ResearchKit is our top story of the year. Mobile apps and the increasing ability to take measurements of vital signs, gather information on habits and collect other phenotypic measures is rapidly changing thinking about clinical trials design.

Medical Device Business Strategies

Industry Roundup: FDA Investigation Prompts Criminal Charges Against Supplement Marketer

Watson opens supplement ingredient database; FTC shuts down melanoma app marketer; Amway’s Nutrilite wins halal award; more news in brief.

Consumer Medical Device

Industry Roundup: FDA Investigation Prompts Criminal Charges Against Supplement Marketer

Watson opens supplement ingredient database; FTC shuts down melanoma app marketer; Amway’s Nutrilite wins halal award; more news in brief.

Consumer Medical Device

Seeking New Options for Prostate Cancer

Recent reports questioning the benefits of early prostate cancer diagnosis and treatment have raised an industry-wide debate that has been fueled by the limitations of prostate-specific antigen tests, currently the standard of care for early prostate cancer detection. While the industry searches to improve the use of PSA tests, urologists are asking, "are we over treating our patients?" That question was repeatedly voiced in a number of forums at the American Urological Association's 2010 Annual Meeting. As for a definitive answer to the question, it is a somewhat difficult task to get individual physicians to admit they are personally over treating patients; however, there is definitely a consensus-and a concern-that more patients than necessary are receiving treatments that put them at risk of serious side effects.
Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
      • Genomics-Proteomics
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
    • Urine-based Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Direct Wireless Communications Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Health Discovery Corp.
  • Senior Management
  • John Norris, CEO
    Ramananda Madyastha, MD, PhD, SVP, R&D
    Thomas L Gallagher, Pres. & COO
    John Hadden, SVP, National & International Bus. Dev.
  • Contact Info
  • Health Discovery Corp.
    Phone: (912) 443-1987
    2 East Bryan St., Ste. 601
    Savannah, GA 31401
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register